This Month in JNM

Small-molecule probes for apoptosis: Reshef and colleagues provide an overview of current approaches in developing highly specific probes suitable for clinical PET imaging of apoptosis and emphasize the importance of multidisciplinary contributions.
Page 837

Monitoring response with ¹⁸F-FLT PET: Weber reviews current work and highlights unanswered questions about the utility of this tracer for imaging tumor cell proliferation in a range of research and clinical oncologic applications.
Page 841

¹⁸F-FLT PET/CT in germ cell tumors: Pfannenberg and colleagues determine the value added by imaging with this tracer to ¹⁸F-FDG PET in early response monitoring and prediction in patients with metastatic germ cell tumors.
Page 845

Nonlaxative PET/CT colonography: Taylor and colleagues investigate the technical feasibility and diagnostic performance of combined nonlaxative PET/CT colonography in patients at higher risk of colorectal neoplasia.
Page 854

PET/CT plaque imaging: Derlin and colleagues assess ¹⁸F-sodium fluoride PET/CT for imaging mineral deposition in arterial wall alterations and the potential of this technique to provide relevant information about morphologic and functional properties of calcified plaque.
Page 862

¹⁸F-FLT PET/CT in oropharyngeal cancer: Troost and colleagues monitor early response with serial ¹⁸F-FLT PET/CT imaging in patients with oropharyngeal tumors to identify subvolumes with high proliferative activity eligible for dose escalation.
Page 866

⁶⁸Ga-DOTATATE PET in NETs: Srirajaskanthan and colleagues evaluate the role of ⁶⁸Ga-DOTATATE PET in patients with negative or weakly positive findings on ¹¹¹In-DTPA-octreotide scintigraphy to determine whether PET detects additional disease and positively affects management decisions.
Page 875

1-¹¹C-acetate PET and meningiomas: Liu and colleagues compare the merits of this PET tracer and those of ¹⁸F-FDG in detection of meningiomas and in monitoring the effects of γ-knife radiosurgery.
Page 883

Clinical imaging of HER2 expression: Baum and colleagues investigate the utility of a human epidermal growth factor receptor 2–targeting Affibody molecule for detection and characterization of HER2-positive lesions in patients with recurrent metastatic breast cancer.
Page 892

⁸²Rb PET/CT reference ranges: Bravo and colleagues establish reference values for left ventricular ejection fraction, end-systolic volume, and end-diastolic volume using 4 different commercial software packages and assess 2 approaches for defining a “healthy” individual.
Page 898

PET and cardiac allograft vasculopathy: Wu and colleagues evaluate the efficacy of dynamic ¹³N-ammonia PET in identifying early stages of allograft vasculopathy and discuss the potential for beneficial management decisions after heart transplantation.
Page 906

¹⁸F-AV-45 AD imaging: Wong and colleagues describe the results of a study of this amyloid-β PET tracer in cognitively healthy controls and patients with Alzheimer disease to determine its ability to provide objective measures for evaluation of late-life cognitive impairment.
Page 913

Quantitative accuracy of ^99mTc SPECT/CT: Zeintl and colleagues present a calibration method for quantitative ^99mTc SPECT in a clinical SPECT/CT device, including ordered-subset expectation maximization with depth-dependent 3D resolution recovery, CT-based attenuation correction, and scatter correction.
Page 921

Variations in dosimetry with obesity: Clark and colleagues describe dose assessment phantoms that model the influence of obesity on specific absorbed fractions and dose factors in adults.
Page 929

Anti–polyethylene glycol reporter gene: Chuang and colleagues describe the construction of a versatile and nonimmunogenic reporter gene to noninvasively image gene expression or cell delivery by optical imaging, MR imaging, and small-animal PET.
Page 933

HER1-targeted immunoPET: Nayak and colleagues report on preclinical development of ⁸⁶Y-CHX-A″-DTPA-panitumumab for quantitative PET of epidermal growth factor receptor–expressing carcinoma.
Page 942

Novel gene delivery and PET: Watanabe and colleagues outline a new methodology for gene therapy, using nanobubbles and ultrasound for nonviral gene delivery and PET and bioluminescence imaging for gene transfer detection.
Page 951

Imaging VEGFR after sunitinib: Levashova and colleagues determine whether noninvasive SPECT of vascular endothelial growth factor receptors, a target of antiangiogenic drugs, can provide real-time information on tumor responses to treatment.
Page 959

ImmunoPET with ¹²⁴I-ch806: Lee and colleagues describe a PET-based method for detecting a constitutively active epidermal growth factor receptor associated with disease progression and resistance to chemo- and radiotherapy in glioma.
Page 967

Nephrotoxicity after ¹¹¹In SPECT: Melis and colleagues explore renal toxicity and radiation dose in a series of ¹¹¹In-labeled peptides using serial SPECT assessments in mice and discuss the implications for long-term renal damage with this tracer.
Page 973

Visualizing siRNA delivery: Kang and colleagues detail a novel ^99mTc-radiolabeled method to image small-interference RNA targeting of a tumor biomarker of human telomerase reverse transcriptase in HepG2 tumor xenografts.
Page 978

RIT survey: Schaefer and colleagues report the results of an e-mail survey assessing the opinions of U.S. oncologists and hematologists on experiences with and challenges to CD20-directed radioimmunotherapy.
Page 987

ON THE COVER

Molecular imaging using the ¹¹¹In- or ⁶⁸Ga-labeled Affibody molecule ABY-002 has the potential to localize metastatic lesions in vivo, adds qualitative information not available by conventional techniques, and may allow the HER2 status to be determined for metastases not amenable to biopsy. In the patient shown here, a potential metastasis in the chest wall near the axilla was shown with ⁶⁸Ga-ABY-002 but was not visible with ¹⁸F-FDG.

See page 895.